Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 4:40 p.m. ET / 1:40 p.m. PT.
A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005962/en/
Xencor Inc. Stock
Xencor Inc. is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
Based on the current price of 15.4 € the target price of 31 € shows a potential of 101.3% for Xencor Inc. which would more than double the current price.